Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

So the active ingredient is “Rlf-100”…

https://www.sec.gov/Archives/edgar/data/1719406/000119312521118931/d56937dex1041.htm?fbclid=IwAR11lJ0oa1E8aZwpX1gVRugC_hccZKfD_PPYvjWhPwfgGIFWmBb_KT7ZdOU

~ Baxter Crewz, Y@h00 RLFTF finance conversations

Replies ————————————

https://www.sec.gov/Archives/edgar/data/1719406/000000000021002365/filename1.pdf

Business of NeuroRX, page 173

14. We note your references throughout to ZYESAMI, RLF-100, VIP and aviptadil. Based on the disclosure throughout your document, each of these terms appears to be a reference to the same product candidate. To the extent this is true, revise your disclosure to refer to this product candidate consistently throughout. Alternatively, please revise the beginning of this section to clearly explain the differences between ZYESAMI, RLF-100, VIP and aviptadil.

FirstName LastName
Richard Ackerman

Company Name
Big Rock Partners Acquisition Corp.

February 26, 2021 Page 4

~ Geert, Y@h00 RLFTF finance conversations

————————>

@Geert BRPA S-4 filings Product Designations

01/27/2021 ZYESAMI (RLF-100)
04/16/2021 ZYESAMI (Reformulation of RLF-100)
05/12/2021 ZYESAMI (Reformulation of RLF-100)
05/19/2021 ZYESAMI (Reformulation of RLF-100)
05/20/2021 ZYESAMI (Reformulation of RLF-100)
05/21/2021 ZYESAMI (Reformulation of RLF-100)

The first BRPA filing on 01/27/2021 confirms the letter. ZYESAMI = RLF-100. All of the subsequent filings refer to ZYESAMI being a reformulation of RLF-100. The inference is that ZYESAMI is based on Relief technology.

~ Raven, Y@h00 RLFTF finance conversations